[Thrombolytic therapy in stroke. What do clinical tests prove?].
Despite the increased risk of intracranial haemorrhage associated with the use of thrombolytic treatment of stroke. American studies have shown patients treated with rt-PA (recombinant plasminogen activator) within three hours of the onset of symptoms to manifest 30 per cent less disability at three-month follow-up than those placebo. However, until satisfactory criteria for the use of rt-PA are available, caution is essential, and thrombolytic therapy should be restricted to specialised centres. It is also important to promote public awareness of the stroke patient's need of immediate treatment at a specialised stroke unit.
Lindberg
P J
PJ
Neurokliniken Helsingfors Universitetscentralsjukhus.
Kaste
M
M
D000208:Acute Disease; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D010919:Placebos; D010960:Plasminogen Activators / Q000627:therapeutic use*; D015912:Thrombolytic Therapy; D016896:Treatment Outcome
D010919:Placebos; D010960:Plasminogen Activators